Oasmia Pharmaceutical AB announces the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs with effect from October 1, 2021. The appointments significantly strengthen Oasmia's internal drug development expertise as the company progresses its portfolio of cancer therapies through the clinic and evaluates opportunities to further expand the pipeline through M&A and in-licensing. Kia Bengtsson was previously Director, Drug Development, at the Swedish nanotechnology company Nanologica, with responsibility for pre-clinical and clinical development. In more than 20 years at leading pharma and biotech companies, Kia has worked on the development of innovative therapies including SomatulineTM for the treatment of neuroendocrine tumors and DecapeptylTM for the treatment of prostate cancer. She held leading positions in drug development and clinical operations at Ipsen, AstraZeneca and Eurocine Vaccines. Kia began her career as a registered nurse at Karolinska University Hospital.